Abstract
TREM2 is a microglial receptor, sensitive to Phospholipids and Sphingomyelins, associated with neurodegeneration. Hypomorphic variants in the TREM2 gene significantly increase the risk of developing AD.
The main aim of this study was to characterize networks of lipids in post-mortem brain from AD and control donors, and to identify key lipids that are associated with AD and impacted by dysfunctional TREM2.
We studied human post-mortem brain tissue from the hippocampus and the BA9 pre-association cortex from a total of 102 post-mortem brains. Specifically, brain tissue from the BA9 pre-association cortex was available for n=55 donors and brain tissue from the hippocampus was available for n=47 brain donors from three groups: AD donors with a non-synonymous risk DNA variant in TREM2 (AD-TREM2var), AD donors with no TREM2-associated variant (AD-TREM2wt), and control donors. Mass Spectrometry was performed to obtain lipidomic signatures spanning 99 lipid species that included the following lipid classes: Ceramides, Sphingomyelins, Phosphatidic acids, Phopshatidyl-cholines, Phosphatidyl-ethalonamines, Phosphatidyl-glycerols, Phosphatidyl-inositols, Phosphatidyl-serines and Triglycerides. Weighted gene co-expression network analysis (WGCNA) was used to identify highly correlated lipid modules and ‘hub’ lipids. Linear mixed models and linear regression analyses, adjusted for age, biological sex, number of APOEε4 alleles and post-mortem delay were used to assess the association of modules and individual hub lipids with AD and TREM2 status.
Four lipid modules were found to be relatively well-preserved between the two brain regions, and three of these modules were altered in AD donors and/or in AD donors with TREM2 genetic variants. Levels of the BA9 “turquoise” module (“blue” hippocampus module), enriched in Sphingolipids and Phospholipids, were elevated in AD brain donors and in AD TREM2 carriers. The key lipid (hub) of the BA9 “turquoise”/ hippocampus “blue” module was a Phosphatidylserine (PS(32:1)), increased in both AD donors and TREM2 carriers (AD-TREM2wt versus controls: beta=0.468, 95% CI 0.05 – 0.89, p= 3.02E-02; and AD-TREM2var versus controls: beta=1.00, 95% CI 0.53 – 1.47, p= 5.57E-03), whereas the strongest association was observed with a Ceramide (Cer(d38:1)) (AD-TREM2wt versus controls: beta=0.663, 95% CI 0.17 – 1.16, p= 8.9E-03; and AD-TREM2var versus controls: beta=1.31, 95% CI 0.78 – 1.84, p= 4.35E-06).
The consistent increase in TREM2 ligands such as Ceramides and Phosphatidyl-serines in the brains of AD donors, particularly in carriers of TREM2 risk variants, could reflect the presence of AD-associated damage signals in the form of stressed/apoptotic cells and damaged myelin.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Petroula Proitsi is funded through an Alzheimers Research UK Senior Research Fellowship
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent for all brain donors was obtained according to the Declaration of Helsinki (1991) and protocols and procedures were approved by the relevant ethical committee and by each brain bank. Brain tissue was provided following project approval by the London Neurodegenerative Diseases Brain Bank (LNDBB). LNDBB subjects were approached in-life for written consent for brain banking, and all tissue donations were collected, stored and distributed following legal and ethical approval (Wales REC 3 favourable opinion 17 Sep 2013, REC number 08/MRE09/38+5; LBBND HTA license number 12293).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
